We reported recently the development of two novel antibodies against an antigen with high level of expression in pancreatic cancer (i.e. CD109) using the human pancreatic cancer cell line BxPC-3 (derived from a primary tumour) as the source of tumour immunogen9,16. Here, CD109 is linked to neoplasm.